Bastion Therapeutics Limited

Bastion Therapeutics Ltd, a small company based in London, UK, has been active since its founding six years ago in 2018. With just three employees and a virtual address shared by over 1,400 other companies, it operates as an irregular importer of miscellaneous chemical products, with its last import activity occurring in July 2024. The company is led by three directors and has one owner, Newton Timothy Mark.

Bastion Therapeutics’ website reveals a fascinating, albeit now-closed, venture into cellular therapies. The company focused on developing treatments for inflammatory disorders using its GRIT Platform, aiming to restore balance within the immune system. It appears the company has shut down operations, with the website stating that its headquarters has closed and the team is moving on to new paths. The company’s mission was to provide curative therapies and address the root cause of inflammatory disorders, targeting a global market of over 600 million people. The company's core business was research and experimental development on biotechnology.

Financially, Bastion Therapeutics Ltd shows a mixed picture. While cash reserves have dramatically increased by 3800% to £320,000, net assets have plummeted by 1300% to £410,000. Creditors have also risen significantly, increasing by 45% to £54,000, while debtors have surged by 780% to £120,000. Property, plant, and equipment have tripled in value, reaching £23,000. The company’s small size—meeting two of three conditions for being classified as small—allows for agility, but the substantial equity drop suggests a possible burn rate. The company is exempt from an audit as a small company. It’s clear that Bastion Therapeutics experienced a period of rapid growth, followed by a sudden closure, leaving its financial future uncertain.

Registered in England/Wales under the registration number 11597069, with a registered address at N3 1XW, United Kingdom, London, 35 Ballards Lane.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.